These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25434635)

  • 1. Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
    Floquet A; Vergote I; Colombo N; Fiane B; Monk BJ; Reinthaller A; Calvert P; Herzog TJ; Meier W; Kim JW; del Campo JM; Friedlander M; Pisano C; Isonishi S; Crescenzo RJ; Barrett C; Wang K; Mitrica I; du Bois A
    Gynecol Oncol; 2015 Jan; 136(1):37-42. PubMed ID: 25434635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Burger RA; Brady MF; Rhee J; Sovak MA; Kong G; Nguyen HP; Bookman MA
    Gynecol Oncol; 2013 Oct; 131(1):21-6. PubMed ID: 23906656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
    Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
    Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
    Vergote I; du Bois A; Floquet A; Rau J; Kim JW; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Colombo N; Mirza MR; Monk BJ; Tsibulak I; Calvert PM; Herzog TJ; Hanker LC; Meunier J; Lee JY; Bologna A; Carrasco-Alfonso MJ; Harter P
    Gynecol Oncol; 2019 Nov; 155(2):186-191. PubMed ID: 31519320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.
    Kim JW; Mahner S; Wu LY; Shoji T; Kim BG; Zhu JQ; Takano T; Park SY; Kong BH; Wu Q; Wang KL; Ngan HY; Liu JH; Wei LH; Mitrica I; Zhang P; Crescenzo R; Wang Q; Cox CJ; Harter P; du Bois A
    Int J Gynecol Cancer; 2018 Jan; 28(1):2-10. PubMed ID: 26588236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    Aghajanian C; Bookman MA; Fleming GF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Jackson CG; Sullivan D; Ratajczak CK; Coleman RL
    Gynecol Oncol; 2021 Aug; 162(2):375-381. PubMed ID: 34112513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
    Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
    Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
    Reyners AKL; de Munck L; Erdkamp FLG; Smit WM; Hoekman K; Lalisang RI; de Graaf H; Wymenga ANM; Polee M; Hollema H; van Vugt MATM; Schaapveld M; Willemse PHB;
    Ann Oncol; 2012 Nov; 23(11):2896-2902. PubMed ID: 22689176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dense approaches to ovarian cancer treatment.
    Katsumata N
    Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
    du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
    J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
    Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
    J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
    Kristeleit R; Davidenko I; Shirinkin V; El-Khouly F; Bondarenko I; Goodheart MJ; Gorbunova V; Penning CA; Shi JG; Liu X; Newton RC; Zhao Y; Maleski J; Leopold L; Schilder RJ
    Gynecol Oncol; 2017 Sep; 146(3):484-490. PubMed ID: 28698009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.
    Fagotti A; Vizzielli G; Fanfani F; Costantini B; Ferrandina G; Gallotta V; Gueli Alletti S; Tortorella L; Scambia G
    Gynecol Oncol; 2013 Nov; 131(2):341-6. PubMed ID: 23938372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
    Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
    Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
    O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
    Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.